DaVita Inc. (NYSE: DVA) announced that the United States Attorney's Office (USAO) for St. Louis recently informed the company that the USAO completed its investigation and is not taking any action against the company.
In March 2005, the St. Louis USAO initiated its inquiry with a subpoena and subsequent document requests in connection with a joint civil and criminal investigation. The broad requests covered a range of topics including financial relationships with physicians and joint ventures. They also covered other services provided to patients, including the administration and billing of Epogen®. DaVita® fully cooperated with the government investigation, providing hundreds of thousands of documents. The USAO closed its investigation without filing any charges, without demanding any payments and without seeking any changes in company policies.
DaVita has a strong thirteen year record of compliance and works hard to create and sustain a culture of compliance. DaVita respects the government's right to inquire about questions it has relating to complex regulatory matters and appreciates the government’s willingness to work to resolve these matters.
DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2012, DaVita operated or provided administrative services at 1,884 outpatient dialysis centers located in the United States serving approximately 149,000 patients. The company also operated 19 outpatient dialysis centers located in four countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit